190 related articles for article (PubMed ID: 35048417)
1. Mechanism of anti-inflammatory effects of rifampicin in an ex vivo culture system of hidradenitis suppurativa.
Haferland I; Wallenwein CM; Ickelsheimer T; Diehl S; Wacker MG; Schiffmann S; Buerger C; Kaufmann R; Koenig A; Pinter A
Exp Dermatol; 2022 Jul; 31(7):1005-1013. PubMed ID: 35048417
[TBL] [Abstract][Full Text] [Related]
2. Clindamycin versus clindamycin plus rifampicin in hidradenitis suppurativa treatment: Clinical and ultrasound observations.
Caposiena Caro RD; Cannizzaro MV; Botti E; Di Raimondo C; Di Matteo E; Gaziano R; Bianchi L
J Am Acad Dermatol; 2019 May; 80(5):1314-1321. PubMed ID: 30502416
[TBL] [Abstract][Full Text] [Related]
3. Why rifampin (rifampicin) is a key component in the antibiotic treatment of hidradenitis suppurativa: a review of rifampin's effects on bacteria, bacterial biofilms, and the human immune system.
Scheinfeld N
Dermatol Online J; 2016 Jun; 22(6):. PubMed ID: 27617596
[TBL] [Abstract][Full Text] [Related]
4. Clindamycin and rifampicin combination therapy for hidradenitis suppurativa.
Mendonça CO; Griffiths CE
Br J Dermatol; 2006 May; 154(5):977-8. PubMed ID: 16634904
[TBL] [Abstract][Full Text] [Related]
5. Lymecycline vs. clindamycin plus rifampicin in hidradenitis suppurativa treatment: clinical and ultrasonography evaluation.
Caposiena Caro RD; Molinelli E; Brisigotti V; Offidani A; Bianchi L
Clin Exp Dermatol; 2021 Jan; 46(1):96-102. PubMed ID: 32683727
[TBL] [Abstract][Full Text] [Related]
6. The anti-inflammatory potency of biologics targeting tumour necrosis factor-α, interleukin (IL)-17A, IL-12/23 and CD20 in hidradenitis suppurativa: an ex vivo study.
Vossen ARJV; Ardon CB; van der Zee HH; Lubberts E; Prens EP
Br J Dermatol; 2019 Aug; 181(2):314-323. PubMed ID: 30657173
[TBL] [Abstract][Full Text] [Related]
7. Adalimumab (antitumour necrosis factor-α) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study.
van der Zee HH; Laman JD; de Ruiter L; Dik WA; Prens EP
Br J Dermatol; 2012 Feb; 166(2):298-305. PubMed ID: 22013960
[TBL] [Abstract][Full Text] [Related]
8. The Bacteriology of Skin Lesions in Patients with Hidradenitis Suppurativa Is Associated with Previous Antibiotic Treatment in the Community Setting: A Referral Center Experience.
Barmatz S; Fisch-Gilad S; Hackett A; Barak Levitt J; Dalal A; Taieb Y; Kremer N; Levi A; Pavlovsky L; Hodak E; Yahav D; Sherman S
Dermatology; 2022; 238(4):772-784. PubMed ID: 35086093
[TBL] [Abstract][Full Text] [Related]
9. Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.
Lovrić I; Brkić J; Ćorluka M; Čović M; Pejić J; Zeljko Penavić J
Acta Dermatovenerol Croat; 2021 Jul; 29(2):108-110. PubMed ID: 34477078
[TBL] [Abstract][Full Text] [Related]
10. Oral clindamycin and rifampicin combination therapy for hidradenitis suppurativa: a prospective study and 1-year follow-up.
Dessinioti C; Zisimou C; Tzanetakou V; Stratigos A; Antoniou C
Clin Exp Dermatol; 2016 Dec; 41(8):852-857. PubMed ID: 27753139
[TBL] [Abstract][Full Text] [Related]
11. Biofilm production and antibiotic susceptibility of Staphylococcus epidermidis strains from Hidradenitis Suppurativa lesions.
Ardon CB; Prens EP; Fuursted K; Ejaz RN; Shailes J; Jenssen H; Jemec GBE
J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):170-177. PubMed ID: 30022542
[TBL] [Abstract][Full Text] [Related]
12. The Microbiology of Hidradenitis Suppurativa.
Ring HC; Emtestam L
Dermatol Clin; 2016 Jan; 34(1):29-35. PubMed ID: 26617355
[TBL] [Abstract][Full Text] [Related]
13. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β.
van der Zee HH; de Ruiter L; van den Broecke DG; Dik WA; Laman JD; Prens EP
Br J Dermatol; 2011 Jun; 164(6):1292-8. PubMed ID: 21332464
[TBL] [Abstract][Full Text] [Related]
14. Adalimumab versus Rifampicin Plus Clindamycin for the Treatment of Moderate to Severe Hidradenitis Suppurativa: A Retrospective Study.
Marasca C; Annunziata MC; Villani A; Volpe S; Marasca D; Fabbrocini G
J Drugs Dermatol; 2019 May; 18(5):437-438. PubMed ID: 31141853
[TBL] [Abstract][Full Text] [Related]
15. The critical role of macrophages in the pathogenesis of hidradenitis suppurativa.
Shah A; Alhusayen R; Amini-Nik S
Inflamm Res; 2017 Nov; 66(11):931-945. PubMed ID: 28656364
[TBL] [Abstract][Full Text] [Related]
16. Serum high-sensitivity C-reactive protein, tumor necrosis factor-α, interleukin (IL)-1β, IL-17A and IL-23 levels in patients with hidradenitis suppurativa.
Saraç Öztürk G; Ergun T; Peker Eyüboğlu İ; Akkiprik M
Cytokine; 2021 Aug; 144():155585. PubMed ID: 34034145
[TBL] [Abstract][Full Text] [Related]
17. Primary alterations during the development of hidradenitis suppurativa.
Dajnoki Z; Somogyi O; Medgyesi B; Jenei A; Szabó L; Gáspár K; Hendrik Z; Gergely P; Imre D; Póliska S; Törőcsik D; Zouboulis CC; Prens EP; Kapitány A; Szegedi A
J Eur Acad Dermatol Venereol; 2022 Mar; 36(3):462-471. PubMed ID: 34724272
[TBL] [Abstract][Full Text] [Related]
18. Novel Therapeutic Approaches and Targets for the Treatment of Hidradenitis Suppurativa.
Giuffrida R; Cannavò SP; Coppola M; Guarneri C
Curr Pharm Biotechnol; 2021; 22(1):59-72. PubMed ID: 32368973
[TBL] [Abstract][Full Text] [Related]
19. Keratinocytes and immune cells in the epidermis are key drivers of inflammation in hidradenitis suppurativa providing a rationale for novel topical therapies.
Schell SL; Cong Z; Sennett ML; Gettle SL; Longenecker AL; Goldberg SR; Kirby JS; Helm MF; Nelson AM
Br J Dermatol; 2023 Feb; 188(3):407-419. PubMed ID: 36680309
[TBL] [Abstract][Full Text] [Related]
20. Rifampicin and clindamycin for hidradenitis.
Wall D; Kirby B
J Am Acad Dermatol; 2011 Apr; 64(4):790. PubMed ID: 21414503
[No Abstract] [Full Text] [Related]
[Next] [New Search]
